Artivion (NYSE:AORT) Shares Gap Up – Here’s Why

Shares of Artivion, Inc. (NYSE:AORT) gapped up before the market opened on Wednesday . The stock had previously closed at $26.53, but opened at $27.21. Artivion shares last traded at $27.55, with a volume of 34,778 shares trading hands.

Analysts Set New Price Targets

AORT has been the topic of several research reports. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price objective on shares of Artivion in a research note on Friday, September 27th. Oppenheimer boosted their target price on shares of Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. JMP Securities began coverage on shares of Artivion in a research note on Wednesday. They set an “outperform” rating and a $33.00 target price for the company. Stifel Nicolaus upped their target price on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, Lake Street Capital upped their target price on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $30.60.

Artivion Stock Up 2.9 %

The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.04 and a current ratio of 5.63. The company has a market cap of $1.14 billion, a P/E ratio of -110.54 and a beta of 1.74. The firm’s 50-day simple moving average is $25.80 and its 200 day simple moving average is $24.58.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.04. The business had revenue of $98.02 million for the quarter, compared to analyst estimates of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. On average, research analysts forecast that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Artivion

In other news, VP Matthew A. Getz sold 9,420 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $25.31, for a total value of $238,420.20. Following the completion of the transaction, the vice president now owns 34,116 shares in the company, valued at $863,475.96. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Matthew A. Getz sold 9,420 shares of Artivion stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the transaction, the vice president now owns 34,116 shares in the company, valued at approximately $863,475.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at $3,664,912.02. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,109 shares of company stock valued at $951,935 in the last 90 days. 8.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Artivion

A number of hedge funds and other institutional investors have recently bought and sold shares of AORT. GAMMA Investing LLC grew its holdings in Artivion by 38.6% during the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after purchasing an additional 505 shares during the period. Register Financial Advisors LLC bought a new stake in shares of Artivion during the first quarter worth approximately $114,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Artivion by 291.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock worth $118,000 after acquiring an additional 4,154 shares during the period. Wasatch Advisors LP boosted its holdings in shares of Artivion by 108.8% during the first quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock worth $22,928,000 after acquiring an additional 564,549 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of Artivion by 5.0% during the first quarter. Principal Financial Group Inc. now owns 220,445 shares of the company’s stock worth $4,665,000 after acquiring an additional 10,479 shares during the period. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.